{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:55:42Z","timestamp":1774486542445,"version":"3.50.1"},"reference-count":65,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T00:00:00Z","timestamp":1602633600000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Oncopeptides"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2020,10,2]]},"DOI":"10.1080\/13543784.2020.1808884","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T14:38:12Z","timestamp":1600094292000},"page":"1069-1078","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":20,"title":["Melflufen for relapsed and refractory multiple myeloma"],"prefix":"10.1080","volume":"29","author":[{"given":"Albert","family":"Oriol","sequence":"first","affiliation":[{"name":"Institut Josep Carreras and Institut Catal\u00e0 d\u2019Oncologia, Hospital Germans Trias I Pujol, Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Larocca","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero-Universitaria Citt\u00e0 Della Salute E Della Scienza Di Torino, University of Torino, Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9822-4170","authenticated-orcid":false,"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[{"name":"Department of Hematology, H\u00f4pital De La Mil\u00e9trie, CHU De Poitiers, Poitiers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Hajek","sequence":"additional","affiliation":[{"name":"Department of Hemato-Oncology, University of Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hani","family":"Hassoun","sequence":"additional","affiliation":[{"name":"Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Rodr\u00edguez-Otero","sequence":"additional","affiliation":[{"name":"Department of Hematology, Cl\u00ednica Universidad De Navarra, Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agne","family":"Paner","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Stem Cell Transplant, Rush University Medical Center, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredrik H.","family":"Schjesvold","sequence":"additional","affiliation":[{"name":"Oslo Myeloma Center, Oslo University Hospital and K.G. Jebsen Centre for B-Cell Malignancies, University of Oslo, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Gullbo","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Division of Clinical Pharmacology, Uppsala University, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041875"},{"key":"cit0002","unstructured":"Howlader NNA, Krapcho M, Miller D, et al. (eds). SEER Cancer Statistics Review, 1975-2016. Bethesda (MD): National Cancer Institute. https:\/\/seer.cancer.gov\/csr\/1975_2016\/,basedonNovember2018SEERdatasubmission,postedtotheSEERwebsite,April2019. https:\/\/seercancergov\/statfacts\/html\/mulmyhtmlAccessedJan28, 2020"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2007.0017"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-405985"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.09.001"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx096"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30354-1"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805762"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70440-1"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-665018"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30165-X"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2020.1708721"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000560720.92988.e3"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0282-1"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18420"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30044-2"},{"key":"cit0019","volume-title":"Poster presented at: 61st American Society of Hematology Annual Meeting and Exposition","author":"Mateos MV","year":"2019"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124815"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2009.01.004"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506348"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.329"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.217448"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000561772.61511.5b"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2017.1317589"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0200-1"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-743203"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.138"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0024"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455"},{"key":"#cr-split#-cit0035.1","unstructured":"Karyopharma. Press release. Karyopharm announces FDA approval of XPOVIO\u2122 (selinexor) for the treatment of patients with relapsed or refractory multiple myeloma. 2019 [January 10"},{"key":"#cr-split#-cit0035.2","unstructured":"cited 2020 Apr 21]. Available from: https:\/\/investors.karyopharm.com\/news-releases\/news-release-details\/karyopharm-announces-fda-approval-xpoviotm-selinexor-treatment"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"#cr-split#-cit0037.1","unstructured":"Squibb B-M Press release. Bristol-myers squibb and bluebird bio announce positive top-line results from the pivotal phase 2 karmma study of ide-cel in relapsed and refractory multiple myeloma. 2019 [2020 Mar 6"},{"key":"#cr-split#-cit0037.2","unstructured":"cited 2020 Apr 21]. Available from: https:\/\/news.bms.com\/press-release\/corporatefinancial-news\/bristol-myers-squibb-and-bluebird-bio-announce-positive-top-li"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126660"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30576-X"},{"key":"cit0040","unstructured":"U.S. National Library of Medicine ClinicalTrials.gov. Study of CC-93269, a BCMA x CD3 T cell engaging antibody, in subjects with relapsed and refractory multiple myeloma. 2018 [cited 2020 Apr 21]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03486067"},{"key":"cit0041","unstructured":"U.S. National Library of Medicine ClinicalTrials.gov. First in Human (FIH) Study of REGN5458 in patients with relapsed or refractory multiple myeloma. 2018 [cited 2020 Apr 21]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03761108"},{"key":"cit0042","unstructured":"U.S. National Library of Medicine ClinicalTrials.gov. Assessment of AMG 420 in subjects with relapsed and\/or refractory multiple myeloma (AMG420) 2019 [cited 2020 Apr 21]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03836053"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02657"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122895"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126818"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3752"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1007\/s00726-013-1648-0"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0735"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01826.x"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2009.12.022"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1080\/10611860310001647140"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14065"},{"key":"cit0053","volume-title":"Poster presented at: American Association for Cancer Research (AACR) Annual Meeting","author":"Slipicevic A","year":"2020"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-007-9092-1"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-412783"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-015-0299-2"},{"key":"cit0057","unstructured":"Oncopeptides. Summary \u2013 our clinical studies. 2020 [cited 2020 Apr 21]. Available from: https:\/\/oncopeptides.se\/en\/our-clinical-trials-summary\/"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-070209-175325"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2018.1538777"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-2074-2"},{"key":"cit0061","unstructured":"Oncopeptides. Oncopeptides to apply for accelerated approval in the US. 2020 [cited 2020 Apr 21]. Available from: https:\/\/oncopeptidesse\/en\/oncopeptides-to-apply-for-accelerated-approval-in-the-us\/"},{"key":"cit0062","unstructured":"Oncopeptides. FDA grants priority review of melflufen for patients with triple-class refractory multiple myeloma. [cited 2020 Sep 15]. Available from: https:\/\/oncopeptides.se\/en\/fda-grants-priority-review-of-melflufen-for-patients-with-triple-class-refractory-multiple-myeloma\/"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0141-0"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2020.1808884","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T05:26:20Z","timestamp":1620451580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2020.1808884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10,2]]}},"alternative-id":["10.1080\/13543784.2020.1808884"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2020.1808884","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-06-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}